Curcumin analogue A501 induces G2/M arrest and apoptosis in non-small cell lung cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 16, 2014, Pages 6893-6898

  Xia, Yi Qun ^a,b   Wei, Xiao Yan ^a   Li, Wu Lan ^a,c   Kanchana, Karvannan ^a   Xu, Chao Chao ^a,b   Chen, Da Hui ^a   Chou, Pei Hong ^a   Jin, Rong ^b   Wu, Jian Zhang ^a   Liang, Guang ^a  

^a School of Pharmaceutical Science   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor; Apoptosis; Curcumin; Cycle arrest; NSCLC

Indexed keywords

ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CASPASE 3; CCNB1 PROTEIN, HUMAN; CDK1 PROTEIN, HUMAN; CURCUMIN; CYCLIN B1; CYCLIN DEPENDENT KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANALOGS AND DERIVATIVES; APOPTOSIS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; HUMAN; LUNG NEOPLASMS; M PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; CYCLIN B1; CYCLIN-DEPENDENT KINASES; HUMANS; LUNG NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919773829     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.16.6893     Document Type: Article

References (32)

1. Afaq F, Adhami VM, Ahmad N, et al (2002). Botanical antioxidants for chemoprevention of photocarcinogenesis. Front Biosci, 7, 784-92.
2. Aggarwal BB, Shishodia S (2006). Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol, 71, 1397-421.
3. Anand P, Kunnumakkara AB, Newman RA, et al (2007). Bioavailability of curcumin: problems and promises. Mol Pharm, 4, 807-18.
4. Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev, 14, 3855-9.
5. Dempke WC, Suto T, Reck M (2010). Targeted therapies for non-small cell lung cancer. Lung cancer, 67, 257-74.
6. Fang X, Fang L, Gou S, et al (2013). Design and synthesis of dimethylaminomethyl-substituted curcumin derivatives/analogues: Potent antitumor and antioxidant activity, improved stability and aqueous solubility compared with curcumin. Bioorg Med Chem Lett, 23, 1297-301.
7. Kamat AM, Tharakan ST, Sung B, et al (2009). Curcumin potentiates the antitumor effects of bacillus calmette-guerin against bladder cancer through the downregulation of NFkappaB and upregulation of TRAIL receptors. Cancer Res, 69, 8958-66.
8. Kunnumakkara AB, Anand P, Aggarwal BB (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett, 269, 199-225.
9. Kunnumakkara AB, Guha S, Krishnan S, et al (2007). Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factorkappaB-regulated gene products. Cancer Res, 67, 3853-61.
10. Li PM, Li YL, Liu B, et al (2014). Curcumin inhibits MHCC97H liver cancer cells by activating ROS/TLR-4/caspase signaling pathway. Asian Pac J Cancer Prev, 15, 2329-34.
11. Li Y, Zhang S, Geng JX, Hu XY (2013). Curcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome C. Asian Pac J Cancer Prev, 14, 4599-602.
12. Liang G, Shao L, Wang Y, et al (2009). Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem, 17, 2623-31.
13. Lin SS, Huang HP, Yang JS, et al (2008). DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade-and mitochondrial-dependent pathway. Cancer Lett, 272, 77-90.
14. Liu Z, Tang L, Zou P, et al (2014). Synthesis and biological evaluation of allylated and prenylated mono-carbonyl analogs of curcumin as anti-inflammatory agents. Eur J Med Chem, 74, 671-82.
15. Mo N, Li ZQ, Li J, et al (2012). Curcumin inhibits TGF-beta1-induced MMP-9 and invasion through ERK and Smad signaling in breast cancer MDA-MB-231 cells. Asian Pac J Cancer Prev, 13, 5709-14.
16. Nagai S, Kurimoto M, Washiyama K, et al (2005). Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J Neurooncol, 74, 105-11.
17. Ohori H, Yamakoshi H, Tomizawa M, et al (2006). Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther, 5, 2563-71.
18. Pal SK, Figlin RA, Reckamp K (2010). Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther, 9, 1931-44.
19. Prakobwong S, Gupta SC, Kim JH, et al (2011). Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis, 32, 1372-80.
20. Selvam C, Jachak SM, Thilagavathi R, et al (2005). Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett, 15, 1793-7.
21. Selvendiran K, Tong L, Vishwanath S, et al (2007). EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem, 282, 28609-18.
22. Sharma RA, Steward WP, Gescher AJ (2007). Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol, 595, 453-70.
23. Starakis I, Nikolakopoulos A, Mazokopakis EE (2012). Targeted therapies for advanced non-small cell lung cancer. Comb Chem High T Scr, 15, 641-55.
24. Strimpakos AS, Sharma RA (2008). Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Sign, 10, 511-45.
25. Subramaniam D, May R, Sureban SM, et al (2008). Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res, 68, 1962-9.
26. Tong QS, Zheng LD, Lu P, et al (2006). Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells. Anti-cancer drugs, 17, 279-87.
27. Valentini A, Conforti F, Crispini A, et al (2009). Synthesis, oxidant properties, and antitumoral effects of a heteroleptic palladium (II) complex of curcumin on human prostate cancer cells. J Med Chem, 52, 484-91.
28. Wang Y, Xiao J, Zhou H, et al (2011). A novel monocarbonyl analogue of curcumin, (1E, 4E)-1, 5-bis (2, 3-dimethoxyphenyl)penta-1, 4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. J Med Chem, 54, 3768-78.
29. Wu SH, Hang LW, Yang JS, et al (2010). Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade-and mitochondriadependent pathways. Anticancer Res, 30, 2125-33.
30. Xiao J, Chu Y, Hu K, et al (2010). Synthesis and biological analysis of a new curcumin analogue for enhanced antitumor activity in HepG 2 cells. Oncol Rep, 23, 1435-41.
31. Zhang X, Zhang HQ, Zhu GH, et al (2012). A novel monocarbonyl analogue of curcumin induces apoptosis in ovarian carcinoma cells via endoplasmic reticulum stress and reactive oxygen species production. Mol Med Rep, 5, 739-44.
32. Zhao C, Liu Z, Liang G (2013). Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs). Curr Pharm Design, 19, 2114-35.